Answers are grounded in this paper and cite their sources.
Demonstrates that 3'-sialyllactose inhibits melanoma cell invasion, suggesting a potential therapeutic agent.
Malignant melanoma has a high mortality rate and is aggressive. The development, metastasis, and angiogenesis of melanoma have all been connected to toll-like receptor 4 (TLR4). However, signal transduction mediated by TLR4 for accelerating melanoma progression is fully unclear. Because of this, the current research has been carried out to explore drug candidate possibility using 3'-Sialyllactose (3'-SL). We investigated the inhibitory effect of 3'-SL on migration and invasion, which are associated with treatment difficulty and mortality. The suppression of matrix metalloproteinases 9 (MMP-9) expression and activity by 3'-SL in B16F10 murine melanoma cells and concurrently downregulated the MAPK signaling pathway involved in this regulation. Therefore, our results demonstrate that 3'-SL may be a good candidate for the development of therapeutic agents to suppress malignancy associated with metastasis and invasion.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: